Peter Gerhard Friedrich Hentschel
Director/Board Member chez Lumina Adhesives AB
Profil
Peter Gerhard Friedrich Hentschel is currently the Director at Lumina Adhesives AB since 2009.
He previously held various director positions at different firms including Rls Global AB, Genizon Biosciences, Inc., Carmel Pharma AB, Unomedical A, Kirudan A, Diasend AB, Appeartex AB, SentoClone AB, Medeikonos AB, Reapplix A, and Bactiguard Holding AB.
He was also the Senior VP-Wound Care & Surgical Division at Mölnlycke Health Care Group AB from 1998 to 2006.
Hentschel graduated from Chalmers University of Technology with a graduate degree and from the University of Gothenburg with an undergraduate degree.
Postes actifs de Peter Gerhard Friedrich Hentschel
| Sociétés | Poste | Début |
|---|---|---|
Lumina Adhesives AB
 Lumina Adhesives AB Industrial SpecialtiesProcess Industries Lumina Adhesives AB provides switchable medical adhesive. It develops a Lumina Film dressing which consists of a thin polyurethane membrane, coated with a layer of switchable acrylic adhesive. It offers medical dressing that lose adhesion when exposed to visible light. The firm's products are used on fragile surfaces, including skin. The company was founded by Stefan Karl Wilhelm Svahn and Daniel Jacobsson in 2008 and is headquartered in Gothenburg, Sweden. | Director/Board Member | 01/01/2009 |
Anciens postes connus de Peter Gerhard Friedrich Hentschel
| Sociétés | Poste | Fin |
|---|---|---|
| RLS GLOBAL AB (PUBL) | Chairman | 02/08/2017 |
Appeartex AB
 Appeartex AB BiotechnologyHealth Technology Appeartex AB operates as a biotechnology company which engages in the development and renewal of antimicrobial solutions for non-woven material, protective clothing, medical supplies, and cleaning and hygiene-related items. It produces water-based formulations that are used in surface treatment applications in the restaurant and catering, healthcare, veterinary, animal care sectors. The company was founded by Lars Schönemyr in 2003 and is headquartered in Gothenburg, Sweden. | Director/Board Member | 01/01/2014 |
SentoClone AB
 SentoClone AB Miscellaneous Commercial ServicesCommercial Services SentoClone AB is a Swedish scientific research company developing SentoClone® - a patented method where the immune defense system is activated and strengthened to combat cancer. SentoClone is registered with the European Medicines Ageny, EMEA, as an SME (small and medium sized enterprises). SentoClone AB is a member of the IML, The Swedish Association for small and medium-sized companies active in R&D. SentoClone AB is owned by a number of venture capital firms, among them Stena Adactum AB, Sahltech i Göteborg AB and T-bolaget AB, together with founders Ola Winqvist and Magnus Thörn. | Director/Board Member | 31/12/2012 |
Genizon Biosciences, Inc.
 Genizon Biosciences, Inc. BiotechnologyHealth Technology Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population. Genizon has one of the largest GWAS programs worldwide, addressing many common diseases and traits. Several of these have been successfully completed, generating comprehensive maps of interacting genes, biomarkers and biological disease pathways (known as GeneMaps), providing strong validation of the power of the Company's discovery platform. Genizon has out-licensed some of the therapeutic and diagnostic rights to GeneMaps for Crohn's disease (to Genentech) and attention deficit hyperactivity disorder, endometriosis and Alzheimer's disease (disease-state diagnostic rights to Pfizer). GeneMaps have also been generated from GWAS in schizophrenia, psoriasis and longevity. GWAS are in progress for rheumatoid arthritis, Alzheimer's disease, and coronary heart disease and its precursors, obesity, type II diabetes, dyslipidemia and hypertension (collectively metabolic syndrome). Genizon's technology platform and discoveries can complement current R&D programs by using human genetics to significantly enhance research and by adding value at multiple stages of the drug development process. Genizon is continually developing and enhancing its gene and biomarker discovery platform. For example, the company is assessing the role of copy number variations (CNVs) in diseases- applying new methods to ongoing large-scale GWAS in rheumatoid arthritis and metabolic syndrome, and retrospectively to previous studies. Genizon also leverages its platform and expertise by offering high throughput, high quality SNP genotyping, statistical genetics, gene expression and pharmacogenomics services to academic institutions, research organizations and the biopharmaceutical industry. | Director/Board Member | 30/05/2012 |
Carmel Pharma AB
 Carmel Pharma AB Electronic Equipment/InstrumentsElectronic Technology Carmel Pharma AB manufactures PhaSeal System, a clinically proven closed-system drug transfer device (CSTD) for the safe handling of hazardous drugs. The company expanded its safe handling initiatives to the U.S. market with the formation of Carmel Pharma, Inc., which operates a corporate office and distribution facility out of Columbus, OH. Carmel Pharma AB was founded in 1994 and is headquartered in Gothenburg, Sweden. | Director/Board Member | 01/01/2011 |
Formation de Peter Gerhard Friedrich Hentschel
| Chalmers University of Technology | Graduate Degree |
| University of Gothenburg | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| RLS GLOBAL AB (PUBL) | Health Technology |
| BACTIGUARD HOLDING AB | Health Technology |
| Entreprise privées | 11 |
|---|---|
Genizon Biosciences, Inc.
Genizon Biosciences, Inc. BiotechnologyHealth Technology Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population. Genizon has one of the largest GWAS programs worldwide, addressing many common diseases and traits. Several of these have been successfully completed, generating comprehensive maps of interacting genes, biomarkers and biological disease pathways (known as GeneMaps), providing strong validation of the power of the Company's discovery platform. Genizon has out-licensed some of the therapeutic and diagnostic rights to GeneMaps for Crohn's disease (to Genentech) and attention deficit hyperactivity disorder, endometriosis and Alzheimer's disease (disease-state diagnostic rights to Pfizer). GeneMaps have also been generated from GWAS in schizophrenia, psoriasis and longevity. GWAS are in progress for rheumatoid arthritis, Alzheimer's disease, and coronary heart disease and its precursors, obesity, type II diabetes, dyslipidemia and hypertension (collectively metabolic syndrome). Genizon's technology platform and discoveries can complement current R&D programs by using human genetics to significantly enhance research and by adding value at multiple stages of the drug development process. Genizon is continually developing and enhancing its gene and biomarker discovery platform. For example, the company is assessing the role of copy number variations (CNVs) in diseases- applying new methods to ongoing large-scale GWAS in rheumatoid arthritis and metabolic syndrome, and retrospectively to previous studies. Genizon also leverages its platform and expertise by offering high throughput, high quality SNP genotyping, statistical genetics, gene expression and pharmacogenomics services to academic institutions, research organizations and the biopharmaceutical industry. | Health Technology |
Mölnlycke Health Care Group AB
 Mölnlycke Health Care Group AB Medical SpecialtiesHealth Technology Mölnlycke Health Care manufactures and markets single-use surgical and wound care products. The firm's surgical division offers surgical solutions through a range of single-use products that help minimize the risk of infections for patients, protect healthcare workers and increase the efficiency in the operating room. Its brands include: BARRIER, Biogel and HiBi. The company is headquartered in Gothenburg, Sweden. | Health Technology |
Carmel Pharma AB
Carmel Pharma AB Electronic Equipment/InstrumentsElectronic Technology Carmel Pharma AB manufactures PhaSeal System, a clinically proven closed-system drug transfer device (CSTD) for the safe handling of hazardous drugs. The company expanded its safe handling initiatives to the U.S. market with the formation of Carmel Pharma, Inc., which operates a corporate office and distribution facility out of Columbus, OH. Carmel Pharma AB was founded in 1994 and is headquartered in Gothenburg, Sweden. | Electronic Technology |
Unomedical A/S
 Unomedical A/S Medical SpecialtiesHealth Technology Unomedical A/S manufactures and distributes medical devices. It offers catheters, surgical aids, electrocardiography electrodes, general nursing products, drainage bags, wound care products, and infusion devices. The company is headquartered in Lejre, Denmark. | Health Technology |
| Kirudan A/S | |
Diasend AB
 Diasend AB Packaged SoftwareTechnology Services Diasend AB provides communication platform between care providers and patients. Its system consolidates data from multiple glucose meters and insulin pumps into one single report, irrespective of device brand. The company was founded in 2004 and is headquartered in Askim, Sweden. | Technology Services |
Appeartex AB
Appeartex AB BiotechnologyHealth Technology Appeartex AB operates as a biotechnology company which engages in the development and renewal of antimicrobial solutions for non-woven material, protective clothing, medical supplies, and cleaning and hygiene-related items. It produces water-based formulations that are used in surface treatment applications in the restaurant and catering, healthcare, veterinary, animal care sectors. The company was founded by Lars Schönemyr in 2003 and is headquartered in Gothenburg, Sweden. | Health Technology |
SentoClone AB
SentoClone AB Miscellaneous Commercial ServicesCommercial Services SentoClone AB is a Swedish scientific research company developing SentoClone® - a patented method where the immune defense system is activated and strengthened to combat cancer. SentoClone is registered with the European Medicines Ageny, EMEA, as an SME (small and medium sized enterprises). SentoClone AB is a member of the IML, The Swedish Association for small and medium-sized companies active in R&D. SentoClone AB is owned by a number of venture capital firms, among them Stena Adactum AB, Sahltech i Göteborg AB and T-bolaget AB, together with founders Ola Winqvist and Magnus Thörn. | Commercial Services |
| Medeikonos AB | |
Reapplix A/S
 Reapplix A/S Medical DistributorsDistribution Services Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark. | Distribution Services |
Lumina Adhesives AB
Lumina Adhesives AB Industrial SpecialtiesProcess Industries Lumina Adhesives AB provides switchable medical adhesive. It develops a Lumina Film dressing which consists of a thin polyurethane membrane, coated with a layer of switchable acrylic adhesive. It offers medical dressing that lose adhesion when exposed to visible light. The firm's products are used on fragile surfaces, including skin. The company was founded by Stefan Karl Wilhelm Svahn and Daniel Jacobsson in 2008 and is headquartered in Gothenburg, Sweden. | Process Industries |
